# Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00049192** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (estimated)

## Conditions studied

- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Phase Chronic Myelogenous Leukemia
- Relapsing Chronic Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00049192
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049192, "Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00049192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*